Thiazolidinediones – some recent developments

Bibliography

• SCHOONJANS K, AUWERX J: Thiazolidinediones: an update. Lancet (2000) 355:1008–1010.
   PubMed Web of Science ®Google Scholar
• OLEFSKY JM: Treatment of insulin resistance with perwdsome proliferator-activated receptor-y agonists. Clin. Invest. (2000) 106:467–472.
   Google Scholar
• MATTHAEI S, STUMVOLL M, KELLERER M, HARING HU: Pathophsiology and pharmacological treatment of insulin resistance. Endocc Rev. (2000) 21:585–618.
   PubMed Web of Science ®Google Scholar
• STUMVOLL M, HARING HU: Glitazones: clinical effects and molecular mechanisms. Ann. Med. (2002) 34:217–224.
   PubMed Web of Science ®Google Scholar
• MURPHY E, NOLAN JJ: Insulin sensitiserdrugs. Expert Opin. Investig. Drugs (2000) 9:1347–1361.
   PubMed Web of Science ®Google Scholar
• WAGSTAFF AJ, GOA KL: Rosiglitazone: areview of its use in the management of Type 2 diabetes mellitus. Drugs (2002) 62: 1805-1837.
   Google Scholar
• PARULKAR AA, PENDERGRASS ML, GRANDA-AYALA R, LEE TR, FONSECA VA: Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med. (2001) 134:61–71.
   PubMed Web of Science ®Google Scholar
• NOLAN JJ, LUDVIK B, BEERDSEN P, JOYCE M, OLEFSKY J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl. Med. (1994) 331:1188–1193.
   PubMed Web of Science ®Google Scholar
• ROMUALDI D, GUIDO M, CIAMPELLI M et al.: Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum. Reprod. (2003) 18:1210–1218.
   PubMed Web of Science ®Google Scholar
• EHRMANN DA, SCHNEIDER DJ, SOBEL BE et al.: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome. Clin. Endocrinol Metab. (1997) 82:2108–2116.
   Google Scholar
• IMANO E, KANDA T, KAWAMORI R, KAJIMOTO Y, YAMASAKI Y: Pioglitazone-reduced insulin resistance in patient with Werner syndrome. Lancet (1997) 350:1365.
   PubMed Web of Science ®Google Scholar
• BODEN G, SHULMAN GI: Free fatty acids in obesity and Type 2 diabetes: defining their role in the development of insulin resistance and I3-cell dysfunction. Eur. Clin. Invest. (2002) 32 (Suppl. 3):14–23.
   Google Scholar
• FRIEDMAN JM, HALAAS JL: Leptin andthe regulation of body weight in mammals. Nature (1998) 395:763–770.
   PubMed Web of Science ®Google Scholar
• BERTI L, KELLERER M, CAPP E, HARING HU: Leptin stimulates glucose transport and glycogen synthesis in C2C12 myotubes: evidence for a P13-kinase mediated effect. Diabetologia (1997) 40:606–609.
   PubMed Web of Science ®Google Scholar
• COHEN B, NOVICK D, RUBINSTEIN M: Modulation of insulin activities by leptin. Science (1996) 274:1185–1188.
   PubMed Web of Science ®Google Scholar
• ORAL EA, SIMHA V, RUIZ E et al: Leptin-replacement therapy for lipodystrophy. N Engl. I Med. (2002) 346:570–578.
   PubMed Web of Science ®Google Scholar
• HOTAMISLIGIL GS, ARNER P, ATKINSON RL, SPIEGELMAN BM: Differential regulation of the p80 tumour necrosis factor receptor in human obesity and insulin resistance. Diabetes (1997) 46:451–455.
   PubMed Web of Science ®Google Scholar
• MOHAMED-ALI V, GOODRICK S, BULMER K, HOLLY JM, YUDKIN JS, COPPACK SW: Production of soluble tumour necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am. J. Physiol (1999) 277:E971–E975.
   PubMed Web of Science ®Google Scholar
• OFEI F, HUREL S, NEWKIRK J, SOP WITH M, TAYLOR R: Effects of an engineered human antiTNF-a antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes (1996) 45:881–885.
   PubMed Web of Science ®Google Scholar
• PAQUOT N, CASTILLO MJ, LEFEBVRE PJ, SCHEEN AJ: No increased insulin sensitivity after a single intravenous administration of a recombinant human tumour necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. Clin. Endocrinol Metab. (2000) 85:1316–1319.
   Google Scholar
• STEPPAN CM, BAILEY ST, BHAT S et al.: The hormone resistin links obesity to diabetes. Nature (2001) 409:307–312.
   PubMed Web of Science ®Google Scholar
• STUMVOLL M, HARING H: Resistin and adiponectin: of mice and men. Obes. Res. (2002).
   Google Scholar
• WEYER C, FUNAHASHI T, TANAKA S et al.: Hypoadiponectinemia in obesity and Type 2 diabetes: close association with insulin resistance and hyperinsulinemia. Clin. Endocrinol Metab. (2001) 86:1930–1935.
   Google Scholar
• TAKAHASHI M, ARITA Y, YAMAGATA K et al.: Genomic structure and mutations in adipose-specific gene, adiponectin. Int. I Obes. Relat. Metab. Disord. (2000) 24:861–868.
   PubMed Web of Science ®Google Scholar
• YANG WS, LEE WJ, FUNAHASHI T et al.: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. I Clin. Endocrinol Metab. (2001) 86:3815–3819.
   PubMed Web of Science ®Google Scholar
• TSCHRITTER 0, FRITSCHE A, THAMER C et al.: Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes (2003) 52:239–243.
   Google Scholar
• COMBS TP, BERG AH, OBICI S, SCHERER PE, ROSSETTI L: Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. Clin. Invest. (2001) 108:1875–1881.
   Google Scholar
• YAMAUCHI T, KAMON J, WAKI H et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. (2001) 7:941–946.
   PubMed Web of Science ®Google Scholar
• STEFAN N, STUMVOLL M: Adiponectin - role in metabolism and beyond. Holm. Metab. Res. (2002) 34(9):469–474.
   PubMed Web of Science ®Google Scholar
• YAMAUCHI T, KAMON J, ITO Y et at: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature (2003) 423(6941):762–769.
   PubMed Web of Science ®Google Scholar
• DEBRIL MB, RENAUD JP, FAJAS L, AUWERX J: The pleiotropic functions of perwdsome proliferator-activated receptor-y. Ma Med. (2001) 79:30–47.
   PubMed Web of Science ®Google Scholar
• DESVERGNE B, WAHLI W: Perwdsome proliferator-activated receptors: nuclear control of metabolism. Endocc Rev (1999) 20:649–688.
   PubMed Web of Science ®Google Scholar
• FORMAN BM, TONTONOZ P, CHEN J, BRUN RP, SPIEGELMAN BM, EVANS RIVI: 15-Deoxy-8-12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR-y. Cell (1995) 83:803–812.
   PubMed Web of Science ®Google Scholar
• FRANCIS GA, FAYARD E, PICARD F, AUWERX J: Nuclear receptors and the control of metabolism. Ann. Rev Physiol (2003) 65:261–311.
   PubMed Web of Science ®Google Scholar
• LOVISCACH M, REHMANN N, CARTER L et al.: Distribution of perwdsome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia (2000) 43:304–311.
   PubMed Web of Science ®Google Scholar
• HOTAMISLIGIL GS, SHARGILL NS, SPIEGELMAN BM: Adipose expression of tumour necrosis factor-a: direct role in obesity-linked insulin resistance. Science (1993) 259:87–91.
   PubMed Web of Science ®Google Scholar
• PARK KS, CIARALDI TP, ABRAMS CARTER L, MUDALIAR S, NIKOULINA SE, HENRY RR: Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese Type II diabetic subjects. J. Clin. Endocrinol Metab. (1998) 83:1636–1643.
   PubMed Web of Science ®Google Scholar
• BURANT CE SREENAN S, HIRANO K et al.: Troglitazone action is independent of adipose tissue. I Clin. Invest. (1997) 100:2900–2908.
   PubMed Web of Science ®Google Scholar
• CHAO L, MARCUS-SAMUELS B, MASON MM et al.: Adipose tissue is required for the antidiabetic but not for the hypolipidemic, effect of thiazolidinediones. Clin. Invest. (2000) 106:1221–1228.
   Google Scholar
• KIM JK, FILLMORE JJ, GAVRILOVA 0et al.: Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes (2003) 52:1311–1318.
   Google Scholar
• YAMAUCHI T, KAMON J, WAKI H et al.: The mechanisms by which both heterozygous PPARy deficiency and PPARy agonist improve insulin resistance., " Biol. Chem. (2001).
   Google Scholar
• OAKES ND, THALEN PG, JACINTO SM, LJUNG B: Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes (2001) 50:1158–1165.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI Y, GLASS L, TRIPLITT C et al.: Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia (2001) 44:2210–2219.
   PubMed Web of Science ®Google Scholar
• MAYERSON AB, HUNDAL RS, DUFOUR S et al.: The effects of rosiglitazone on insulin sensitivity, lipolysis and hepatic and skeletal muscle triglyceride content in patients with Type 2 diabetes. Diabetes (2002) 51:797–802.
   PubMed Web of Science ®Google Scholar
• HOFMANN C, LORENZ K, BRAITHWAITE SS et al.: Altered gene expression for tumour necrosis factor-a and its receptor during drug and dietary modulation of insulin resistance. Endocrinology (1994) 134:264–270.
   PubMed Web of Science ®Google Scholar
• DE VOS P, LEFEBVRE AM, MILLER SG et al.: Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor-y. Clin. Invest. (1996) 98:1004–1009.
   Google Scholar
• MAEDA N, TAKAHASHI M, FUNAHASHI T et al.: PPARy ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes (2001) 50:2094–2099.
   PubMed Web of Science ®Google Scholar
• COMBS TP, WAGNER JA, BERGER Jet al.: Induction of adipocyte complement-related protein of 30 kilodaltons by PPARy agonists: a potential mechanism of insulin sensitization. Endocrinology (2002) 143:998–1007.
   Google Scholar
• YANG WS, JENG CY, WU TJ et al.: Synthetic peroxisome proliferator-activated receptor-y agonist, rosiglitazone, increases plasma levels of adiponectin in Type 2 diabetic patients. Diabetes Care (2002) 25:376–380.
   PubMed Web of Science ®Google Scholar
• YU JG, JAVORSCHI S, HEVENER ALet al.: The effect of thiazolidinediones on plasma adiponectin levels in normal, obese and Type 2 diabetic subjects. Diabetes (2002) 51:2968–2974.
   Google Scholar
• STAIGER H, TSCHRITTER 0, MACHANN J et al.: Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes. Res. (2003) 11:368–372.
   Google Scholar
• MOTOSHIMA H, WU X, SINHA MK et al.: Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. Clin. Endocrinol Metab. (2002) 87:5662–5667.
   Google Scholar
• YAMAUCHI T, KAMON J, MINOKOSHI Y et al.: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. (2002) 8:1288–1295.
   PubMed Web of Science ®Google Scholar
• FRYER LG, PARBU-PATEL A, CARLING D: The antidiabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signalling pathways. I Biol. Chem. (2002) 277:25226–25232.
   Web of Science ®Google Scholar
• ZHOU G, MYERS R, LI Y et al: Role ofAMP-activated protein kinase in mechanism of metformin action.," Clin. Invest. (2001) 108:1167–1174.
   Google Scholar
• ADAMS M, MONTAGUE CT, PRINS JB et al.: Activators of peroxisome proliferator-activated receptor y have depot-specific effects on human preadipocyte differentiation. I Clin. Invest. (1997) 100:3149–3153.
   PubMed Web of Science ®Google Scholar
• MORI Y, MURAKAWA Y, OKADA K et al.: Effect of troglitazone on body fat distribution in Type 2 diabetic patients. Diabetes Care (1999) 22:908–912.
   PubMed Web of Science ®Google Scholar
• AKAZAWA S, SUN F, ITO M, KAWASAKI E, EGUCHI K: Efficacy of troglitazone on body fat distribution in Type 2 diabetes. Diabetes Care (2000) 23:1067–1071.
   PubMed Web of Science ®Google Scholar
• CAREY DG, COWIN GJ, GALLOWAY GJ et al.: Effect of rosiglitazone on insulin sensitivity and body composition in Type 2 diabetic patients. Obes. Res. (2002) 10:1008–1015.
   PubMedGoogle Scholar
• MIYAZAKI Y, MAHANKALI A, MATSUDA M et al.: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in Type 2 diabetic patients. Clin. Endocrinol Metab. (2002) 87:2784–2791.
   Google Scholar
• MONTAGUE CT, O'RAHILLY S: The perils of portliness: causes and consequences of visceral adiposity. Diabetes (2000) 49:883–888.
   PubMed Web of Science ®Google Scholar
• SEPPALA-LINDROOS A, VEHKAVAARA S, HAKKINEN AM et al.: Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. I Clin. Endocrinol Metab. (2002) 87:3023–3028.
   PubMed Web of Science ®Google Scholar
• BACHMANN OP, DAHL DB, BRECHTEL K et al.: Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. Diabetes (2001) 50:2579–2584.
   Web of Science ®Google Scholar
• JACOB S, MACHANN J, RETT K et al.:Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of Type 2 diabetic subjects. Diabetes (1999) 48:1113–1119.
   PubMed Web of Science ®Google Scholar
• KRSSAK M, FALK PETERSEN K, DRESNER A et al.: Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia (1999) 42:113–116.
   PubMed Web of Science ®Google Scholar
• BAJAJ M, SURAAMORNKUL S, PRATIPANAWATR T et al.: Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with Type 2 diabetes. Diabetes (2003) 52:1364–1370.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI Y, HARDIES LJ, WAJCBERG E et al.: Effect of piolgitazone on liver fat content, abdmoninal fat distribution and insulin sensitivity in patients with Type 2 diabetes mellitus (T2DM). Diabetes (2002) 51\(Suppl. 2):A69.
   Google Scholar
• PAN XR, LI GW, HU YH et al.: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care (1997) 20:537–544.
   PubMed Web of Science ®Google Scholar
• KNOWLER WC, BARRETT-CONNOR E, FOWLER SE et al.: Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N Engl. I Med. (2002) 346:393–403.
   PubMed Web of Science ®Google Scholar
• TUOMILEHTO J, LINDSTROM J, ERIKSSON JG et al.: Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl. J. Med. (2001) 344:1343–1350.
   PubMed Web of Science ®Google Scholar
• DPP STUDY GROUP: The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of Type 2 diabetes. Diabetes Care (1999) 22:623–634.
   PubMed Web of Science ®Google Scholar
• FINEGOOD DT, MCARTHUR MD, KOJWANG D et al.: 13-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes (2001) 50:1021–1029.
   Google Scholar
• CAVAGHAN MK, EHRMANN DA, BYRNE MM, POLONSKY KS: Treatment with the oral antidiabetic agent troglitazone improves 13 cell responses to glucose in subjects with impaired glucose tolerance. Clin. Invest. (1997) 100:530–537.
   Google Scholar
• SHIMABUKURO M, ZHOU Y-T, LEE Y, UNGER RH: Troglitazone lowers islet fat and restores 13 cell function of diabetic fatty rats.," Biol. Chem. (1998) 273:3547–3550.
   Google Scholar
• BUCHANAN TA, XIANG AH, PETERS RK et al.: Preservation of pancreatic 13-cellfunction and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes (2002) 51:2796–2803.
   PubMed Web of Science ®Google Scholar
• STUMVOLL M, HARING H: The Prol2Ala polymorphism in the peroxisome proliferator-activated receptor y. Diabetes (2002) 51:2341–2347.
   PubMed Web of Science ®Google Scholar
• BLUHER M, LUBBEN G, PASCHKE R: Analysis of the relationship between the Prol2Ala variant in the PPAR-72 gene and the response rate to therapy with pioglitazone in patients with Type 2 diabetes. Diabetes Care (2003) 26:825–831.
   PubMed Web of Science ®Google Scholar
• YUDKIN JS, KUMARI M, HUMPHRIES SE, MOHAMED-ALI V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis (2000) 148:209–214.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-REAL JM, RICART W: Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia (1999) 42:1367–1374.
   PubMed Web of Science ®Google Scholar
• ROSS R: Atherosclerosis - an inflammatorydisease. N Engl. J. Med. (1999) 340:115–126.
   PubMed Web of Science ®Google Scholar
• LIBBY P, RIDKER PM, MASERI A: Inflammation and atherosclerosis. Circulation (2002) 105:1135–1143.
   PubMed Web of Science ®Google Scholar
• MARX N, SUKHOVA GK, COLLINS T, LIBBY P, PLUTZKY J: PPARa activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation (1999) 99:3125–3131.
   PubMed Web of Science ®Google Scholar
• MARX N, SCHONBECK U, LAZAR MA, LIBBY P, PLUTZKY J: Peroxisome proliferator-activated receptor y activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. (1998) 83:1097–1103.
   PubMed Web of Science ®Google Scholar
• MARX N, SUKHOVA G, MURPHY C, LIBBY P, PLUTZKY J: Macrophages in human atheroma contain PPARy differentiation-dependent percodsomal proliferator-activated receptor y (PPARy) expression and reduction of MMP-9 activity through PPARy activation in mononuclear phagocytes M vitro. Am. J. Pathol. (1998) 153:17–23.
   PubMed Web of Science ®Google Scholar
• MARX N, KEHRLE B, KOHLHAMMER K et al.: PPAR activators as anti-inflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res. (2002) 90:703–710.
   PubMed Web of Science ®Google Scholar
• BECKMAN JA, CREAGER MA, LIBBY P:Diabetes and atherosclerosis: epidemiology, pathophysiology and management. "AMA (2002) 287:2570–2581.
   PubMed Web of Science ®Google Scholar
• JIANG C, TING AT, SEED B: PPAR-y agonists inhibit production of monocyte inflammatory cytokines. Nature (1998) 391:82–86.
   PubMed Web of Science ®Google Scholar
• WELCH JS, RICOTE M, AKIYAMA TE, GONZALEZ FJ, GLASS CK: PPAR{y} and PPARISI negatively regulate specific subsets of lipopolysaccharide and IFN-{7} target genes in macrophages. Proc. Nati Acad. Sci. USA (2003) 100:6712–6717.
   PubMed Web of Science ®Google Scholar
• PASCERI V, WU HD, WILLERSON JT, YEH ET: Modulation of vascular inflammation M vitro and in vivo by peroxisome proliferator-activated receptor-7 activators. Circulation (2000) 101:235–238.
   PubMed Web of Science ®Google Scholar
• RICOTE M, HUANG J, FAJAS L et al.: Expression of the peroxisome proliferator-activated receptor y (PPARy) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Nati Acad. Sci. USA (1998) 95:7614–7619.
   PubMed Web of Science ®Google Scholar
• BRUEMMER D, BERGER JP, LIU J et aL: A non-thiazolidinedione partial peroxisome proliferator-activated receptor y ligand inhibits vascular smooth muscle cell growth. Eur.j Pbarmacol. (2003) 466:225–234.
   PubMed Web of Science ®Google Scholar
• FAVEEUW C, FOUGERAY S, ANGELI V et al.: Peroxisome proliferator-activated receptor y activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett. (2000) 486:261–266.
   PubMed Web of Science ®Google Scholar
• KATO K, SATOH H, ENDO Y et al.: Thiazolidinediones downregulate plasminogen activator inhibitor Type 1 expression in human vascular endothelial cells: A possible role for PPARy in endothelial function. Biothem. Biophys. Res. Commun. (1999) 258:431–435.
   PubMed Web of Science ®Google Scholar
• LI AC, BROWN KK, SILVESTRE MJ, WILLSON TM, PALINSKI W, GLASS CK: Peroxisome proliferator-activated receptor y ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. (2000) 106:523–531.
   PubMed Web of Science ®Google Scholar
• COLLINS AR, MEEHAN WP, KINTSCHER U et al.: Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. A-ter/ostler. Thromb. Vase. Biol. (2001) 21:365–371.
   PubMed Web of Science ®Google Scholar
• YUE TUTU, CHEN J, BAO W et al.: In vivo myocardial protection from ischaemia/reperfusion injury by the peroxisome proliferator-activated receptor-7 agonist rosiglitazone. Circulation (2001) 104:2588–2594.
   PubMed Web of Science ®Google Scholar
• HAFFNER SM, GREENBERG AS, WESTON WM, CHEN H, WILLIAMS K, FREED MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation (2002) 106:679–684.
   PubMed Web of Science ®Google Scholar
• MARX N, IMHOF A, FROEHLICH J et al.: Effect of rosiglitazone treatment on soluble CD4OL in patients with Type 2 diabetes and coronary artery disease. Circulation (2003) 107: 1954-1957.
   Google Scholar
• MARX N, FROEHLICH J, SIAM L et al.:Antidiabetic PPAR 7-activator rosiglitazone reduces MMP-9 serum levels in Type 2 diabetic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. (2003) 23:283–288.
   PubMed Web of Science ®Google Scholar
• TAKAGI T, AKASAKA T, YAMAMURO A et al.: Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. Am. Coll. Cardiol (2000) 36:1529–1535.
   PubMed Web of Science ®Google Scholar
• WANG CH, VVEISEL RD, LIU PP, FEDAK PW, VERMA S: Glitazones and heart failure: critical appraisal for the clinician. Circulation (2003) 107:1350–1354.
   PubMed Web of Science ®Google Scholar
• SCHEEN AJ: Thiazolidinediones and liver toxicity. Diabetes Metab. (2001) 27:305–313.
   PubMed Web of Science ®Google Scholar
• MAEDA K: Hepatocellular injury in a patient receiving pioglitazone. Ann. Intern. Med. (2001) 135:306.
   PubMed Web of Science ®Google Scholar
• AL SALMAN J, ARJOMAND H, KEMP DG, MITTAL M: Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann. Intern. Med. (2000) 132:121–124.
   PubMed Web of Science ®Google Scholar
• FORMAN LM, SIMMONS DA, DIAMOND RH: Hepatic failure in a patient taking rosiglitazone. Ann. Intern. Med. (2000) 132:118–121.
   PubMed Web of Science ®Google Scholar
• BALDWIN SJ, CLARKE SE, CHENERY RJ: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br: J. Clin. Pharmacol (1999) 48:424–432.
   Google Scholar
• ISLEY WL, OKI JC: Rosiglitazone and liver failure. Ann. Intern. Med. (2000) 133:393.
   PubMed Web of Science ®Google Scholar
• GIMBLE JM, ROBINSON CE, WU X et al.: Perwdsome proliferator-activated receptor-7 activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Ma Pharmacol (1996) 50:1087–1094.
   PubMed Web of Science ®Google Scholar
• SAEZ E, TONTONOZ P, NELSON MC et al.: Activators of the nuclear receptor PPARy enhance colon polyp formation. Nat. Med. (1998) 4:1058–1061.
   PubMed Web of Science ®Google Scholar
• LEFEBVRE AM, CHEN I, DESREUMAUX P et al.: Activation of the peroxisome proliferator-activated receptor y promotes the development of colon tumours in C57BL/6J- APCMin/+ mice. Nat. Med. (1998) 4:1053–1057.
   PubMed Web of Science ®Google Scholar
• SARRAF P, MUELLER E, JONES D et al.: Differentiation and reversal of malignant changes in colon cancer through PPARy. Nat. Med. (1998) 4:1046–1052.
   PubMed Web of Science ®Google Scholar
• AUWERXJ: Nuclear receptors. I. PPARy in the gastrointestinal tract: gain or pain? Am. .1. Physiol Castrointest. Liver Physiol (2002) 282:G581–G585.
   Google Scholar
• ADLER A, TURNER RC: The diabetes prevention program. Diabetes Care (1999) 22:543–545.
   PubMed Web of Science ®Google Scholar
• COMBS CK, JOHNSON DE, KARLO JC, CANNADY SB, LANDRETH GE: Inflammatory mechanisms in Alzheimer's disease: inhibition of P-amyloid-stimulated pro-inflammatory responses and neurotoxicity by PPARy agonists. Neurosci. (2000) 20:558–567.
   PubMed Web of Science ®Google Scholar
• WATSON GS, CRAFT S: The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs (2003) 17:27–45.
   PubMed Web of Science ®Google Scholar
• ELBRECHT A, CHEN Y, ADAMS A et al.: L-764406 is a partial agonist of human perwdsome proliferator-activated receptor y. The role of Cys313 in ligand binding. Biol. Chem. (1999) 274:7913–7922.
   Google Scholar
• MUKHERJEE R, HOENER PA, JOW L et al.: A selective peroxisome proliferator-activated receptor-7 (PPARy) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol. Endocrinol (2000) 14:1425–1433.
   PubMed Web of Science ®Google Scholar
• OBERFIELD JL, COLLINS JL, HOLMES CP et al.: A perwdsome proliferator-activated receptor y ligand inhibits adipocyte differentiation. Proc. Nati Acad. Sci. USA (1999) 96:6102–6106.
   PubMed Web of Science ®Google Scholar
• REGINATO MJ, BAILEY ST, KRAKOW SL et al.: A potent antidiabetic thiazolidinedione with unique perwdsome proliferator-activated receptor 7-activating properties. J. Biol. Chem. (1998) 273:32679–32684.
   PubMed Web of Science ®Google Scholar
• BRAND CL, STURIS J, GOTFREDSEN CF et al.: Dual PPARa/y activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am. I Physiol Endocrinol Metab. (2003) 284:E841–E854.
   PubMed Web of Science ®Google Scholar
• YE JM, IGLESIAS MA, WATSON DG et al.: PPARa/y ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am. Physiol Endocrinol Metab. (2003) 284:E531–E540.
   PubMed Web of Science ®Google Scholar